Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenue:
Licensing revenue	$ 341,643
Operating expenses:
Research and development	9,330,677	16,666,335
General and administrative	4,138,285	4,356,381
Total operating expenses	13,468,962	21,022,716
Loss from operations	(13,127,319)	(21,022,716)
Interest income	31,142	66,091
Other income, net	670,781	198,369
Interest expense	(549,403)	(363,629)
Total non-operating income (expenses), net	152,520	(99,169)
Net loss	(12,974,799)	(21,121,885)
Net loss - non-controlling interest	(400,847)	(826,629)
Net loss attributable to Heat Biologics, Inc.	$ (12,573,952)	$ (20,295,256)
Net loss per share attributable to Heat Biologics, Inc.- basic and diluted	$ (0.71)	$ (2.53)
Weighted-average number of common shares used in net loss per share attributable to common stockholders - basic and diluted	17,586,210	8,015,687
Other comprehensive loss:
Net loss	$ (12,974,799)	$ (21,121,885)
Unrealized gain (loss) on foreign currency translation	14,353	(86,584)
Total comprehensive loss	(12,960,446)	(21,208,469)
Comprehensive loss attributable to non-controlling interest	(400,847)	(826,629)
Comprehensive loss	$ (12,559,599)	$ (20,381,840)